• Community News
  • Medical and Scientific News
  • Features
Canadian Hemophilia Society
  • Français
chsLogo
  • Community News
  • Medical and Scientific News
  • Features
Home / Articles posted by David Page (Page 10)
  • Patients’ and caregivers’ “lived experience” crucial in CHS submissions on product access

    By David Page on April 7, 2020

    It’s an exciting time in care for people with bleeding disorders. In recent years, a number of novel therapies have come through clinical trials and...

  • No emicizumab this year for non-inhibitor patients

    By David Page on April 7, 2020

    Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...

Page 10 of 10« First‹ Previous678910
  • KEYWORDS

    ADVOCACY ageing A GLOBAL PERSPECTIVE AIDS CARRIERS CHS chapters Community COMPENSATION COVID-19 EMICIZUMAB GENE THERAPY HALF-LIFE FACTOR CONCENTRATES HEMLIBRA HEMOPHILIA A AND B HEPATITIS C HIV ICHIP INHIBITORS MYCBDR NURSING PHYSIOTHERAPY Platelet function disorders PROBE PROPHYLAXIS RARE BLEEDING DISORDERS RESEARCH SOCIAL WORK Tainted blood tragedy THE BLOOD FACTOR THE FEMALE FACTOR THERAPIES THE SAGE PAGE TWINNING VON WILLEBRAND DISEASE

Copyright © 2020 - Canadian Hemophilia Society. All rights reserved.

  • ARCHIVED HEMOPHILIA TODAY
  • ABOUT US